Having become embroiled in a legal tussle with Roche last week concerning the latter's emicizumab, Shire has licensed a hemophilia A bispecific monoclonal antibody of its own.
Amid growing competition from Roche, Shire PLC is looking to consolidate its position at the top of the hemophilia tree, having inked a licensing pact with Switzerland's Novimmune SA to develop a bispecific antibody for the rare bleeding disorder.
The deal with Novimmune centres around a fully human, bi-specific IgG antibody targeting FIXa and FX for hemophilia A, designed to imitate the body’s natural mechanism of Factor VIII-driven coagulation
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.
Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
